RxDoctor Payments Data

James Richardson, MD

Cardiovascular Disease · Lexington, SCNPI 1558395269

Payments from drug & device makers

$1,896in general payments, 2019–2025

Across 92 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$292
  • Novartis$238
  • Medtronic$236
  • Boston Scientific$205
  • E.r. Squibb & Sons, L.L.C.$179
  • Abbott$151
  • plus $595 from 12 others

What the payments were for

  • Food & beverage$1,82896%
  • Education$684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,896 in reported general payments places this provider in the 30th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$205,072
Medicare patients
659
Services billed
3,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$268,958
Repatha SureclickEvolocumab152$190,185
JardianceEmpagliflozin43$30,106
MultaqDronedarone Hcl23$25,140
EntrestoSacubitril/Valsartan33$23,915
Praluent PenAlirocumab12$15,672
FarxigaDapagliflozin Propanediol18$15,412
Ezetimibe147$4,980
Metoprolol Succinate330$4,789
Valsartan190$4,171
Rosuvastatin Calcium227$3,418
Atorvastatin Calcium226$2,576
Flecainide Acetate56$2,528
Potassium Chloride115$2,087
Clonidine19$2,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$268,958322 claims
Boehringer IngelheimJardiance$12$30,10643 claims
Sanofi-aventis U.S. LLCMultaq$16$25,14023 claims
NovartisEntresto$238$23,91533 claims
AstraZenecaFarxiga$34$15,41218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →